Scarica l'app Stockscreener
30.98
0.10%
0.03
Pre-mercato:
30.89
-0.09
-0.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BAX Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$30.95
Aprire:
$31.01
Volume 24 ore:
3.77M
Relative Volume:
0.93
Capitalizzazione di mercato:
$15.82B
Reddito:
$17.28B
Utile/perdita netta:
$108.00M
Rapporto P/E:
154.90
EPS:
0.2
Flusso di cassa netto:
$391.00M
1 W Prestazione:
+5.30%
1M Prestazione:
+4.52%
6M Prestazione:
-13.17%
1 anno Prestazione:
-19.93%
Intervallo 1D:
$30.51
$31.02
Intervallo di 1 settimana:
$29.24
$31.20
Portata 52W:
$28.34
$44.01
Baxter International Inc Stock (BAX) Company Profile
Nome
Baxter International Inc
Settore
Industria
Telefono
(847) 948-2000
Indirizzo
ONE BAXTER PKWY, DEERFIELD, IL
Confronta BAX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BAX
Baxter International Inc
|
30.98 | 15.82B | 17.28B | 108.00M | 391.00M | 0.20 |
|
ISRG
Intuitive Surgical Inc
|
592.64 | 211.09B | 7.87B | 2.24B | 586.00M | 6.22 |
|
BDX
Becton Dickinson Co
|
237.38 | 68.23B | 20.18B | 1.71B | 3.07B | 5.94 |
|
ALC
Alcon Inc
|
84.37 | 41.73B | 9.76B | 1.16B | 665.00M | 2.34 |
|
RMD
Resmed Inc
|
239.78 | 35.23B | 4.81B | 1.11B | 1.35B | 7.55 |
|
WST
West Pharmaceutical Services Inc
|
336.34 | 24.40B | 2.88B | 499.60M | 321.60M | 6.74 |
Baxter International Inc Stock (BAX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-07-15 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-05-30 | Iniziato | Goldman | Neutral |
| 2024-05-10 | Downgrade | TD Cowen | Buy → Hold |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-03-29 | Iniziato | UBS | Neutral |
| 2023-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-01-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2023-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-12-15 | Downgrade | Deutsche Bank | Buy → Hold |
| 2022-12-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-18 | Iniziato | Barclays | Overweight |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-06-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-18 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2022-02-18 | Reiterato | Morgan Stanley | Overweight |
| 2022-02-18 | Reiterato | Raymond James | Outperform |
| 2022-02-18 | Reiterato | Stifel | Buy |
| 2022-02-18 | Reiterato | UBS | Neutral |
| 2022-02-18 | Reiterato | Wells Fargo | Overweight |
| 2022-02-11 | Iniziato | Goldman | Neutral |
| 2022-01-07 | Ripresa | Citigroup | Buy |
| 2022-01-07 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-09-13 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2021-09-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-05-25 | Iniziato | Barclays | Equal Weight |
| 2021-01-29 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-06 | Downgrade | UBS | Buy → Neutral |
| 2020-12-15 | Downgrade | Goldman | Buy → Neutral |
| 2020-10-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-09-04 | Downgrade | Argus | Buy → Hold |
| 2020-06-24 | Iniziato | Oppenheimer | Outperform |
| 2020-03-19 | Aggiornamento | Stifel | Hold → Buy |
| 2020-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-03-05 | Iniziato | Citigroup | Neutral |
| 2020-02-13 | Iniziato | Goldman | Buy |
| 2020-01-02 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-26 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-04-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-01-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-01-02 | Aggiornamento | Morgan Stanley | Underweight → Overweight |
| 2018-11-02 | Aggiornamento | Argus | Hold → Buy |
| 2018-10-16 | Iniziato | Barclays | Underweight |
| 2018-05-17 | Ripresa | Piper Jaffray | Overweight |
| 2018-02-06 | Reiterato | Citigroup | Neutral |
| 2018-01-03 | Iniziato | Evercore ISI | Outperform |
| 2018-01-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
Mostra tutto
Baxter International Inc Borsa (BAX) Ultime notizie
Hurricane Helene impact on Baxter to further limit IV fluid supply, HHS says - AOL
China Infusion Systems (Pumps & Pump Disposables) Market Outlook to 2033: Key Companies in China, Pipeline Products, Financial Deals Landscape, Recent Developments & More - GlobeNewswire Inc.
Baxter restarts dialysis solutions production at North Cove plant - MSN
Baxter International Inc. stock outperforms competitors on strong trading day - MarketWatch
Should You Hold Baxter International (BAX) for the Long Term? - MSN
Baxter International Inc. (NYSE:BAX) Receives $40.45 Consensus Price Target from Analysts - MarketBeat
Baxter International Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Baxter International Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Small divestitures, acquisitions ahead as Baxter refines strategy - Crain's Chicago Business
Infusion Therapy Market Growth Trends: Regional Breakdown - openPR
Baxter International Inc. (NYSE:BAX) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Baxter International (XSWX:BAX) 3-Year EPS without NRI Grow - GuruFocus.com
Baxter International Inc. stock outperforms competitors despite losses on the day - MarketWatch
Unparalleled Research on Immunoglobulin Market by 2024-2031 | Baxter international Inc., CSL Ltd. - EIN News
U.S. Elastomeric Infusion Pumps Market Set to Witness Significant Growth by 2025-2032: Baxter International - EIN News
U.S. Intravenous Solutions Market Is Booming Worldwide - openPR
Baxter International Inc. stock rises Wednesday, still underperforms market - MarketWatch
How Italian Furniture Maker Baxter Balances Tradition and Innovation - Prestige Online Thailand
Baxter International Inc. stock rises Monday, still underperforms market - MarketWatch
Immunoglobulin Market Generated Opportunities, Future Scope by 2024-2031| Baxter international Inc., CSL Ltd. - EIN News
Baxter International Inc. (NYSE:BAX) Shares Sold by Everence Capital Management Inc. - MarketBeat
Plasma Expander Market Overall Study Report 2025-2032 | Baxter - openPR
Baxter International Inc. stock rises Friday, still underperforms market - MarketWatch
Centre Asset Management LLC Sells 21,904 Shares of Baxter International Inc. (NYSE:BAX) - MarketBeat
Baxter International Inc. (NYSE:BAX) Short Interest Up 6.1% in December - MarketBeat
Earnings Review and Free Research Report: Baxter’s Revenue Grew 6%; EPS Rocketed 96% - AccessWire
BAXTER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Baxter International In - AccessWire
How Is Baxter International's Stock Performance Compared to Other Medical Devices Stocks? - MSN
Investors in Baxter International (NYSE:BAX) have unfortunately lost 64% over the last three years - Simply Wall St
Early Alert: Solution Set Issue from Baxter Healthcare Corporation - FDA.gov
Baxter International (NYSE:BAX) Sets New 52-Week LowWhat's Next? - MarketBeat
Baxter stock touches 52-week low at $28.6 amid market challenges - Investing.com Australia
Should We Be Cautious About Baxter International Inc.'s (NYSE:BAX) ROE Of 1.6%? - Yahoo Finance
Prolotherapy Market Overall Study Report 2024-2031 | Pfizer - openPR
Baxter International Inc Azioni (BAX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.34%
2.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):